These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

483 related items for PubMed ID: 2553921

  • 1. Pharmacological actions of a novel mixed opiate agonist/antagonist: naloxone benzoylhydrazone.
    Gistrak MA, Paul D, Hahn EF, Pasternak GW.
    J Pharmacol Exp Ther; 1989 Nov; 251(2):469-76. PubMed ID: 2553921
    [Abstract] [Full Text] [Related]

  • 2. Naloxone benzoylhydrazone (NalBzoH) analgesia.
    Paul D, Levison JA, Howard DH, Pick CG, Hahn EF, Pasternak GW.
    J Pharmacol Exp Ther; 1990 Nov; 255(2):769-74. PubMed ID: 2173757
    [Abstract] [Full Text] [Related]

  • 3. Pharmacological characterization of nalorphine, a kappa 3 analgesic.
    Paul D, Pick CG, Tive LA, Pasternak GW.
    J Pharmacol Exp Ther; 1991 Apr; 257(1):1-7. PubMed ID: 1850462
    [Abstract] [Full Text] [Related]

  • 4. Antidiarrheal properties of supraspinal mu and delta and peripheral mu, delta and kappa opioid receptors: inhibition of diarrhea without constipation.
    Shook JE, Lemcke PK, Gehrig CA, Hruby VJ, Burks TF.
    J Pharmacol Exp Ther; 1989 Apr; 249(1):83-90. PubMed ID: 2540324
    [Abstract] [Full Text] [Related]

  • 5. Selective antagonism of opioid analgesia by a sigma system.
    Chien CC, Pasternak GW.
    J Pharmacol Exp Ther; 1994 Dec; 271(3):1583-90. PubMed ID: 7996472
    [Abstract] [Full Text] [Related]

  • 6. Mu antagonist and kappa agonist properties of beta-funaltrexamine (beta-FNA) in vivo: long-lasting spinal analgesia in mice.
    Qi JA, Heyman JS, Sheldon RJ, Koslo RJ, Porreca F.
    J Pharmacol Exp Ther; 1990 Mar; 252(3):1006-11. PubMed ID: 2156986
    [Abstract] [Full Text] [Related]

  • 7. Receptor binding of [3H]naloxone benzoylhydrazone: a reversible kappa and slowly dissociable mu opiate.
    Price M, Gistrak MA, Itzhak Y, Hahn EF, Pasternak GW.
    Mol Pharmacol; 1989 Jan; 35(1):67-74. PubMed ID: 2536470
    [Abstract] [Full Text] [Related]

  • 8. Antagonist-induced opioid receptor up-regulation. I. Characterization of supersensitivity to selective mu and kappa agonists.
    Millan MJ, Morris BJ, Herz A.
    J Pharmacol Exp Ther; 1988 Nov; 247(2):721-8. PubMed ID: 2846827
    [Abstract] [Full Text] [Related]

  • 9. The competitive alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate receptor antagonist LY293558 attenuates and reverses analgesic tolerance to morphine but not to delta or kappa opioids.
    Kest B, McLemore G, Kao B, Inturrisi CE.
    J Pharmacol Exp Ther; 1997 Dec; 283(3):1249-55. PubMed ID: 9400000
    [Abstract] [Full Text] [Related]

  • 10. Kappa-opioid receptor-mediated antinociception in the rat. II. Supraspinal in addition to spinal sites of action.
    Millan MJ, Członkowski A, Lipkowski A, Herz A.
    J Pharmacol Exp Ther; 1989 Oct; 251(1):342-50. PubMed ID: 2571723
    [Abstract] [Full Text] [Related]

  • 11. Mu antagonist properties of kappa agonists in a model of rat urinary bladder motility in vivo.
    Sheldon RJ, Nunan L, Porreca F.
    J Pharmacol Exp Ther; 1987 Oct; 243(1):234-40. PubMed ID: 2822899
    [Abstract] [Full Text] [Related]

  • 12. Roles of mu, delta and kappa opioid receptors in spinal and supraspinal mediation of gastrointestinal transit effects and hot-plate analgesia in the mouse.
    Porreca F, Mosberg HI, Hurst R, Hruby VJ, Burks TF.
    J Pharmacol Exp Ther; 1984 Aug; 230(2):341-8. PubMed ID: 6086883
    [Abstract] [Full Text] [Related]

  • 13. Pharmacological characterization of buprenorphine, a mixed agonist-antagonist with kappa 3 analgesia.
    Pick CG, Peter Y, Schreiber S, Weizman R.
    Brain Res; 1997 Jan 02; 744(1):41-6. PubMed ID: 9030411
    [Abstract] [Full Text] [Related]

  • 14. Functional effects of systemically administered agonists and antagonists of mu, delta, and kappa opioid receptor subtypes on body temperature in mice.
    Baker AK, Meert TF.
    J Pharmacol Exp Ther; 2002 Sep 02; 302(3):1253-64. PubMed ID: 12183687
    [Abstract] [Full Text] [Related]

  • 15. Peptide opioid antagonist separates peripheral and central opioid antitransit effects.
    Shook JE, Pelton JT, Hruby VJ, Burks TF.
    J Pharmacol Exp Ther; 1987 Nov 02; 243(2):492-500. PubMed ID: 2824748
    [Abstract] [Full Text] [Related]

  • 16. Differential influence of D1 and D2 dopamine receptors on acute opiate withdrawal in guinea-pig isolated ileum.
    Capasso A, Sorrentino L.
    Br J Pharmacol; 1997 Mar 02; 120(6):1001-6. PubMed ID: 9134209
    [Abstract] [Full Text] [Related]

  • 17. Genetic influences in opioid analgesic sensitivity in mice.
    Pick CG, Cheng J, Paul D, Pasternak GW.
    Brain Res; 1991 Dec 06; 566(1-2):295-8. PubMed ID: 1667610
    [Abstract] [Full Text] [Related]

  • 18. Kappa opioid analgesia is dependent on serotonergic mechanisms.
    Vonvoigtlander PF, Lewis RA, Neff GL.
    J Pharmacol Exp Ther; 1984 Nov 06; 231(2):270-4. PubMed ID: 6092612
    [Abstract] [Full Text] [Related]

  • 19. U-50,488: a selective and structurally novel non-Mu (kappa) opioid agonist.
    Vonvoigtlander PF, Lahti RA, Ludens JH.
    J Pharmacol Exp Ther; 1983 Jan 06; 224(1):7-12. PubMed ID: 6129321
    [Abstract] [Full Text] [Related]

  • 20. Kappa opioid partial agonist activity of the enkephalin-like pentapeptide BW942C based on urination and in vitro studies in humans and animals.
    Vaupel DB, Cone EJ, Johnson RE, Su TP.
    J Pharmacol Exp Ther; 1990 Jan 06; 252(1):225-34. PubMed ID: 2153801
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.